molecules of the month

LEO Pharma IL-17A modulator

oral, allosteric IL-17A inactivator prodrug

Ph. I for psoriasis

SBDD from known compound


LEO Pharma, Ballerup, DK

2 mins read

IL-17 has been a hot target in immunology thanks to the clinical and commercial success of marketed anti-IL-17A and anti-IL-17RA antibody drugs secukinumab (Cosentyx), ixekizumab (Talz), and brodalumab (Siliq) in psoriasis, psoriatic arthritis, and ankylosing sponylitis. With the recent identification of small molecule binders of IL-17A, excitement has grown around the possibility that small molecule alternatives to antibody drugs may be feasible. Cytokines and cytokine receptors like interleukins have traditionally been the domain of biologic drugs due to the need to prevent protein-protein interactions (PPIs) between the cytokines and their receptors. While several companies have patented small molecule IL-17A antagonists, including Ensemble, DiCE, and Lilly, LEO Pharma’s molecule is the most advanced and disclosed oral candidate. The active ingredient was…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: